Evidence map›Paper›PMID 40295397›Full record

ArticleCardiovascular and interventional radiology2025

Microwave Ablation of Colorectal Pulmonary Metastases Offers Excellent Local Tumor Control and Can Prolong Time Off Chemotherapy.

Timothy M Cooke, Constantinos T Sofocleous, Elena N Petre, Erica S Alexander, Etay Ziv, Stephen B Solomon, Vlasios S Sotirchos

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Dielectric properties, thermal properties, blood perfusion rate: which biophysical parameter is the leading source of variability of microwave ablation models in lung?International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Timothy M CookeInterventional Radiology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, H-112B, New York, NY, 10065, USA.
Constantinos T SofocleousInterventional Radiology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, H-112B, New York, NY, 10065, USA.
Elena N PetreInterventional Radiology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, H-112B, New York, NY, 10065, USA.
Erica S AlexanderInterventional Radiology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, H-112B, New York, NY, 10065, USA.
Etay ZivInterventional Radiology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, H-112B, New York, NY, 10065, USA.
Stephen B SolomonInterventional Radiology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, H-112B, New York, NY, 10065, USA.
Vlasios S SotirchosInterventional Radiology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, H-112B, New York, NY, 10065, USA. sotirchv@mskcc.org.ORCID http://orcid.org/0000-0001-7278-1369

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate oncologic outcomes after microwave ablation (MWA) of colorectal pulmonary metastases, with focus on disease control without chemotherapy. MATERIALS AND

methodsThis institutional review board-approved retrospective study examined patients with oligometastatic or oligoprogressive colorectal pulmonary metastases undergoing MWA between January 2011 and December 2021. Imaging response was assessed with CT at 4-8 weeks post-MWA, with subsequent cross-sectional follow-up imaging every 2-4 months. Local tumor progression-free survival (LTPFS), chemotherapy-free survival (CFS) and overall survival (OS) were calculated using Kaplan-Meier methodology. Variables were evaluated for predictive significance using the log-rank test and Cox regression.

resultsTwo hundred twenty-five patients (127 male, 98 female; median age: 55 years) with 720 pulmonary metastases underwent 400 MWA sessions (mean number of treated metastases per session: 1.8; range 1-9). Mean treated tumor size was 0.9 cm. LTPFS at 1, 2 and 3-years was 91.9%, 85.9% and 81.5%, respectively. Tumors ≥ 1 cm in size, pleural-based tumors and pre-MWA carcinoembryonic antigen (CEA) levels ≥ 10 ng/mL were associated with shorter LTPFS (all P < 0.001). 74.7% (168/225) of patients did not receive chemotherapy for at least two months after the initial MWA. Median CFS was 12 months (95% CI 7.8-16.2) and was significantly prolonged in patients with lung-only disease compared to those with concurrent extrapulmonary disease (34.4 vs. 4.0 months, P < 0.001). Median OS was 47 months (95% CI 36.7-57.3).

conclusionMWA of colorectal pulmonary metastases is associated with high local tumor control rates and can offer prolonged CFS, particularly for patients without concurrent extrapulmonary disease.

Indexed as

Colorectal NeoplasmsLung NeoplasmsMicrowavesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesTomography, X-Ray ComputedTreatment OutcomeChemotherapy-free survivalColorectal pulmonary metastasisLocal tumor progressionLung ablationMicrowave ablationOligometastatic disease

Identifiers

PMID40295397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.